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Taxanes remain ﬁrst line chemotherapy in management of metastatic breast cancer and have a key role in epithelial ovarian
cancer, with increasingly common use of weekly paclitaxel dosing regimens. However, their clinical utility is limited by the
development of chemoresistance. To address this, we modelled in vitro paclitaxel resistance in MCF-7 cells. We show that at
clinicallyrelevantdrugdoses,emergingpaclitaxel resistance isassociatedwithprofoundchanges incelldeathresponsesanda
switch from apoptosis to autophagy as the principal mechanism of drug-induced cytotoxicity. This was characterised by a
complete absence of caspase-mediated apoptotic cell death (using the pan-caspase-inhibitor Z-VAD) in paclitaxel-resistant
MCF-7TaxR cells, compared with parent MCF-7 or MDA-MB-231 cell lines on paclitaxel challenge, downregulation of caspase-7,
caspase-9 and BCl2-interacting mediator of cell death (BIM) expression. Silencing with small interfering RNA to BIM in MCF-7
parental cells was sufﬁcient to confer paclitaxel resistance, inferring the signiﬁcance in downregulation of this protein in
contributing to the resistant phenotype of the MCF-7TaxR cell line. Conversely, there was an increased autophagic response in
the MCF-7TaxR cell line with reduced phospho-mTOR and relative resistance to the mTOR inhibitors rapamycin and RAD001. In
conclusion, we show for the ﬁrst time that paclitaxel resistance is associated with profound changes in cell death response with
deletion of multiple apoptotic factors balanced by upregulation of the autophagic pathway and collateral sensitivity to platinum.
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Despite signiﬁcant improvements in clinical outcomes, meta-
static breast cancer (MBC) remains an essentially incurable
disease. The major factor limiting long-term control of MBC is
developmentofchemotherapyresistance.Signiﬁcantadvances
in understanding of some mechanisms of anti-cancer drug
resistance have not been paralleled by introduction of novel
strategies to circumvent or avoid resistance in clinical practice.
A convincing body of experimental evidence implies that
defective apoptosis may be an important mechanism under-
lying chemoresistance.
1–3
Here, we have examined the evolution of paclitaxel
resistance in an MCF-7 cell line,MCF-7TaxR, grown in the
presence of paclitaxel for a limited time period. We have
previously published data regarding the cross-resistance
proﬁle of the MCF-7TaxR line
4 that described upregulation of
ABCB1, but little cross-resistance to the natural product drugs
etoposide, doxorubicin and colchicine. In MCF-7TaxR cells,
we did not see any changes in the expression levels of beta-III
tubulin compared with parental MCF-7 cells (data not shown),
another mechanism cited for paclitaxel resistance.
5 Initial
analyses indicated a marked decrease in the apoptotic
response of paclitaxel-resistant MCF-7 cells to a range
of agents. However, attenuation of apoptosis seen in
MCF-7TaxR cells did not coincide with resistance to many of
those agents. Our investigation set out to explore the under-
lying basis for these changes. Here, we report that the
reduction of apoptosis occurring upon acquisition of paclitaxel
resistance is balanced by upregulation of autophagy as the
principal mechanism of cytotoxicity and cell death.
Results
Paclitaxel-resistant MCF-7 cells show an unusual
spectrum of cross-resistance in the presence of
P-glycoprotein. We tested whether a multidrug resistant
(MDR) phenotype was present by challenging the cells with
doxorubicin and an irrelevant cytotoxic drug cisplatin (Figure 1b).
During the development of paclitaxel resistance, MCF-7
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P-glycoprotein (ﬁrst evident at passage #23 when paclitaxel
resistance was established (Figures 1b and 2a). At this point
in spite of upregulation of MDR1, a multidrug-resistant proﬁle
was not evident in the MCF-7TaxR cells from passage 23
onwards as only a modest increase in doxorubicin resistance
was apparent and resistance to other MDR-associated
agents, including etoposide was not seen.
4 Interestingly,
we saw a collateral sensitivity to cisplatin (Figure 1b) and to
carboplatin (data not shown).
Loss of caspase-7 and -9 is associated with emerging
paclitaxel resistance. As part of the characterisation of the
resistant cell line MCF-7TaxR, we examined the role of
apoptotic cell death response. As part of this analysis, we
assessed expression of caspase-7 and -9 in MCF-7 cells with
increasing resistance to paclitaxel. Downregulation of protein
expression was ﬁrst evident at passage 18 when cells were
establishing resistance at a dose of 6nM paclitaxel and the
messenger ribonucleic acid (mRNA) levels of both genes
was undetectable from passage 23 onwards (Figures 2a
and b). Loss of expression of caspases-7 and -9 was a stable
molecular event as the MCF-7TaxR( ) variant line failed to
show re-expression of either gene following several months
of culture in the absence of paclitaxel.
Development of a paclitaxel-resistant MCF-7 cell line
gives rise to marked changes in pro-and anti-apoptotic
factors. Next, we analysed MCF-7TaxR cells for expression
of pro-and anti-apoptotic proteins. There was a striking
reduction in expression of BIM and BCl2 between passages
18–23, but levels of BCl2-associated death promoter were
stable (Figure 2a).
Absence of BIM as a factor contributing to paclitaxel
resistance. To evaluate a potential role for loss of BIM
underlying the development of paclitaxel resistance, we used
SiRNA to selectively block BIM expression in MCF-7 parental
cells. SiRNA produced efﬁcient downregulation of BIM and on
subsequent challenge with paclitaxel a reduced apoptotic
response was seen (Figure 2c). A series of repeat
experiments showed that at 48h viability in control (non-
silenced) cells following paclitaxel treatment (20nM) were
65.3% (relative to the viable population of the respective
control). The corresponding data for the BIM silenced
population was 85.8%. As indicated in the ﬁgure legend,
these data were shown to be statistically different from each
other. Data indicate that if taken as a factor in isolation, deletion
of BIM is sufﬁcient to confer resistance to paclitaxel in MCF-7
cells.
Paclitaxel-resistant MCF-7 cells show loss of caspase-
mediated cell death. We tested for the ability of apoptotic
induction in paclitaxel-resistant MCF-7TaxR by challenging
cells with staurosporine (an agent frequently used to
demonstrate apoptosis), paclitaxel and cisplatin in the
absence or presence of the pan-caspase inhibitor Z-VAD
using the Annexin V assay with ﬂow cytometric analysis.
Figure 3A indicates the extent of protection afforded by
Z-VAD pre-treatment of cells to a dose of staurosporine.
Figure 3Acindicates the induction of cell death (FITC and
PI-positive populations) and the protective effect afforded
by Z-VAD (Figure 3Ad). Figure 3B indicates the extent of
Z-VAD protection from caspase-mediated staurosporine-
induced cell death in three breast cancer cell lines (n¼4)
based on the size of the viable cell population (lower left-
hand quadrant of panels Figures 3A c and d). Overall, the
involvement of caspase-mediated cell death following
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Figure 1 (a) Schema for development of paclitaxel-resistant cells in culture starting with parental MCF-7 cells at passage 1, week 1. RF indicates resistance factor, RF
(i.e.IC50for resistantvariant:IC50for parentalcells.*Indicatesadrug-freepassagetoenablecellsto recoverfromdrugtreatment.(b)Sensitivityto paclitaxel,doxorubicinand
cisplatin in MCF7 cells with emerging resistance to paclitaxel. MCF-7TaxR cells with increasing resistance to paclitaxel were challenged with the indicated drugs and
cytotoxicity determined using the MTT assay. Data shown are the mean IC50 and S.D. (shown by error bars) of at least four repeat analyses
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Cell Death and Diseasestaurosporine treatment was of the order MDA-MB-
2314MCF-74MCF-7TaxR. MDA-MB231 cells were
chosen as a caspase-proﬁcient line.
6 Figure 3C shows the
effects of cisplatin and paclitaxel following 48h of
continuous exposure. Treatment of cells with Z-VAD
beyond 48h is toxic and therefore, we could only use this
treatment schedule. Moreover, treatment of MCF-7TaxR
cells with a high dose of paclitaxel plus Z-VAD proved much
more toxic than the same dose of paclitaxel alone. Hence,
our data show the effects of 20nM paclitaxel, producing a
loss of viability of approximately 25% in MCF-7 and only 8%
loss of viability in the paclitaxel-resistant MCF-7TaxR line.
Treatment of cells with cisplatin for 48h shows more loss of
viability for MCF-7 than for MCF-7TaxR. This is in contrast
to the MTT data that show relative sensitivity of the
MCF-7TaxR cells to the effects of platinum. It is important
to note that a marked growth-inhibitory effect is seen with
cisplatin and this will be measured by a lack of MTT
reduction in the chemosensitivity testing, and this effect was
pronounced in the MCF-7TaxR line.
Paclitaxel resistance is associated with diminished
apoptotic response but upregulated autophagy. Treatment
of MCF-7 and MCF-7TaxR cells with staurosporine with and
without baﬁlomycin (an inhibitor of autophagic vesicle formation)
then subjected to ﬂow cytometric analysis with acridine orange,
indicated an enhancement of acidic vesicle formation for the
paclitaxel-resistant variant, which was shown to be statistically
signiﬁcantly different for MCF-7TaxR, based on t-test results
(Figure 4a). Thus, treatment of MCF-7 and MCF-7TaxR lines
with staurosporine resulted in a marked stimulation of autophagy
for the latter. Inhibition of mTOR was noted for both MCF cell
lines examined but more apparent for MCF-7TaxR cells, as
seen in the disappearance of phosphorylated AKT,
phophorylated mTOR and also the downstream substrate
p60S6 kinase (p60S6-K), Figure 4b.
Figure 5 shows immunoﬂuorescence for LC-3II using
confocal microscopy, indicating the extent of autophagy
present in staurosporine-treated breast cancer cell lines. For
the caspase-proﬁcient MDA-MB-231 cell line evidence of
LC3II expression was not seen (Figure 5a panel iv), whereas
for MCF-7 presence of the LC-3II form in cells treated with
1mM staurosporine was seen, indicated by the heavy (green)
staining (Figure 5b panel iv). Figure 5c shows the extent of
LC3II formation for the established MCF-7TaxR line, panel iv,
which is the heaviest staining seen for the three cell lines
showing clear autophagosome vesicular formation, shown
more clearly in Figure 5d.
Collateral cisplatin sensitivity is associated with
mTOR inhibition. Using the autophagy inhibitors 3-methyl
adenine and LY294002, we could see signiﬁcant inhibition of
cisplatin cytotoxicity, giving rise to increased IC50 values, as
assessed using the MTT assay, Figure 6a. While the effects
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Figure 2 (a) Western immunoblotting of variant sublines of developing MCF-7TaxR lines. Whole-cell lysates were loaded onto SDS-PAGE gels (NOVEX, Invitrogen) at a
concentration of 50mg and electrophoresis using Tris-Bis gels 10–12% followed by transfer onto PVDF membranes. Primary antibodies to P-glycoprotein (P-gp), Bax, BCl2
were obtained from Santa Cruz, those for caspase-7 and 9, BAD and phosphorylated BAD and BIM were from Cell Signaling Technologies (distributed by New England
Biolabs, Hitchin, UK) and then subjected to incubation with a secondary-alkaline phosphatase-conjugated antibody with subsequent chemiluminescent detection. All
membranes were stripped and reprobed with an antibody to b-actin (Sigma Aldrich), n¼3. (b) Quantitative PCR for assessment of mRNA levels of -7 and -9 on sublines of
developing paclitaxel-resistant MCF-7 cells. Data shown are corrected for GAPDHexpressionusing the equation2 DDCt.( c) Transfection of MCF-7 cells with SiRNA against
BIM(Dharmacon)followedbydrugtreatment(20nMpaclitaxelfor48h)subjectedtoﬂowcytometryusingtheAnnexinVassaywithPI.Thepercentageoflivecells(expressed
asapercentageoftheuntreatedcontrol)isindicatedinthebottomlefthandcorner(PIandFITCnegativecells)ofthequadrantcytogramanddatashownarerepresentativeof
repeat data (n¼3). Comparisons of live populations of non-silenced cells versus BIM-silenced cells gave a P value of 0.03 using a paired t-test. Assessment of efﬁciency of
knockdown of BIM was made by western analysis (as described in Materials and Methods)
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Cell Death and Diseaseof these two inhibitors were shown to be statistically
signiﬁcant in MCF-7 parental cells, the effects were more
pronounced for the MCF-7TaxR cell line when treated with
LY294002. These data provide evidence that the major cell
death response found in MCF-7TaxR cells is autophagy.
Upregulation of the autophagic pathway gives rise to
rapamycin resistance. MCF-7 and MCF-7TaxR cells were
subjected to chemosensitivity testing with rapamycin and the
IC50 values were shown to be 29.4mM( ±7.4) and 64.6mM
(±9.6), respectively, Figure 6b. Using the mTOR inhibitor
RAD001 (IC50 95.5nM-MCF-7; 150nM-MCF-7TaxR), we
could see a gradual reduction in the LC3II form following
treatment with RAD001 (100nM) in MCF-7TaxR cells with
increasing passage number, with the established resistant
line showing MCF-7TaxR that shows negligible amounts of
LC3II formation, Figure 6c. The survivin expression levels
were markedly reduced in the MCF-7 parental cell line
following treatment with RAD001, whereas for the MCF-
7TaxR variant sublines the expression levels of this IAP were
consistently expressed with no variation following drug
treatment. These data also indicate that as the survivin
level in MCF-7 cells were markedly reduced with rapamycin
treatment there is a possibility for some apoptotic induction,
but this effect was not seen for the subvariants of the MCF
paclitaxel-resistant lines. These particular data are
consistent with activation of caspases for the MCF-7
parental line giving rise to activation of the mitochondrial
pathway, whereas for the caspase-9-deﬁcient MCF-7TaxR
passage 18 and 23 variants and the established MCF-7TaxR
line such an effect was not seen.
Discussion
We have derived paclitaxel-resistant MCF-7 human breast
cancercellsusingadrugexposureprotocolsimilartoclinically
used weekly paclitaxel regimens (3 weeks treatment followed
by 1 week off for four cycles
7) and employing drug doses well
within the safety margins for clinical acceptable circulating
levels of paclitaxel, that is, o50nM. We have used parental
and paclitaxel-resistant cell lines to investigate changes in
gene expression and cell death pathways that accompany
paclitaxel resistance. Our data show that there are signiﬁcant
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Figure 3 (A) Cytograms obtained from Annexin V assays of staurosporine (1mM) -treated breast cancer cells. Each cytogram consists of data showing live cells (PI and
FITCnegative)bottomright;earlyapoptoticpopulation(FITCpositive)bottomright;mid-latestageapoptosis(PIandFITCpositive)topright;necrotic/endstageapoptoticcells
(PI positive, FITC negative) top left. a¼control untreated cells; b¼Z-VAD-treated control cells; c¼staurosporine-treated cells; d¼staurosporine and Z-VAD combination
treatment. The live cell population is indicated for each sample and is representative of typical data obtained. (B) Bar graphs (derived from A) showing extent of protection of
staurosporine-treatedcellpopulationfollowingZ¼VADtreatment.*IndicatesP-valueo0.02(usingapairedt-test).(C)CytogramsobtainedforMCF-7andMCF-7TaxRcells
following 48h continuous exposure to cisplatin 20mM in the absence and presence of Z-VAD and for paclitaxel 20nM. Data shown are representative of repeat experiments
and the numbers refer to the mean (and standard deviation) live (PI and FITC negative) populations (expressed as a percentage of the untreated controls) taken from
43 repeat experiments. P-values obtained for MCF-7±Z-VAD with cisplatin¼0.003 and the same ﬁgure obtained for MCF-7TaxR was 40.5; P-values obtained for
MCF-7±Z-VAD with paclitaxel¼0.003 and the same ﬁgure obtained for MCF-7TaxR was 0.5 (using a paired t-test)
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Figure 4 (a) Assessment of autophagic response of breast cancer cell lines to the effects of baﬁlomycin inhibition following treatment with 0.5mM staurosporine. Bar
graphsrepresentthemean(±S.D.) for43 repeat experiments ofthered ﬂuorescencemeasuredinthelowerquadrantof thecytograms.Reducedvaluesindicatemigration
to increased red and green ﬂuorescence with formation of autophagic vesicles and reversal with baﬁlomycin. **P¼0.038, ***P¼0.012 using paired Students t-test.
(b) Western immunoblotting of MCF-7 parental and paclitaxel-resistant cells following treatment with staurosporine. Whole-cell lysates were made of cells following 24 and
48h treatment and subjected to SDS-PAGE electrophoresis using NOVEX Bis-Tris gels (7–12% or 10%) and buffer system. Following transfer to PVDF membranes proteins
were detected using the appropriate rabbit polyclonal antibody (Cell Signaling Technologies, obtained from New England Biolabs, Hitchin, UK) and then subjected to
incubation with a secondary-alkaline phosphatase-conjugated antibody with subsequent chemiluminescent detection. All membranes were stripped and reprobed for actin as
the loading control. Data shown are representative of three repeat experiments
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Figure5 ConfocalﬂuorescencemicroscopyimagingforLC-3detectioninMDA-MB-231,MCF-7andMCF-7TaxRcelllines(a).Cellswereincubatedfor24hwith0.25mM
staurosporine (ii), or 0.5mM staurosporine (iii) and compared with untreated controls (i). Images (i–iii) were co-stained with the nuclear dye TOPRO-3 and images (iv) were
stainedfor LC-3alone(Alexa-Fluor488associatedﬂuorescence).Images(d) (1)and (2)are enlargedimages from(b)(iv) and(c)(iv) showingdepositionof LC3IIgranules in
vacuoles in MCF-7 parental and MCF-7TaxR paclitaxel-resistant lines, respectively
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Cell Death and Diseasechanges in expression of key regulators of cell death
pathways and a striking switch from apoptosis to autophagy
with increasing paclitaxel resistance.
A major ﬁnding in the present study was loss of expression
of caspases-7 and -9 in MCF-7TaxR cells. As the ﬁrst
description of caspase-3 deﬁciency in MCF-7 cells with a
47-bp deletion in exon 3 of the CASP-3 gene
8 an association
of caspase deﬁciency with chemoresistance has been made.
Interestingly, many breast cancer cell lines show weak
expression of caspase-3.
6 Furthermore, it was reported that
75% of primary breast carcinomas have downregulation of
caspase-3 mRNA, as seen in samples taken from breast
cancer patients.
9 Interestingly, peritumoral tissue also
showed low expression of caspase-3, which suggests that
loss of this caspase may be an important mechanism of
survival for breast cancer cells. Those initial ﬁndings have
been independently supported in studies reporting an
association of caspase-3 deﬁciency with poor outcome in
breast cancer.
10 In the present study, we show deletion of
caspases associated with the mitochondrial intrinsic pathway
as a consequence of paclitaxel resistance in human breast
cancer cells. We are not aware of previous reports citing loss
of caspases-7 and -9 in association with taxane resistance.
We are conﬁdent that the effects we are seeing are not
relating any majormitochondrial dysfunction. Asfaras we can
see the function of the mitochondria in the MCF-7TaxR is not
impaired as we saw efﬁcient reduction of MTT in the
cytotoxicity tests used through out this study, and these data
were corroborated by assessment of viability using trypan
blue (not shown). In other studies we carried out we saw that
caspase-8 expression and reactivity to anti-FAS was almost
identical for the parental and paclitaxel-resistant MCF-7 cell
lines alike, (data not shown). This led us to believe that the
modulation of apoptosis we saw in the MCF-7TaxR line was
predominantly relating to the intrinsic pathway.
AsecondimportantobservationwaslossofBIMexpression
inMCF-7TaxR. TheBIM ofcell deathis a potent pro-apoptotic
member of the Bcl2 family,
11 essential for induction of cell
deathandtomediatecytochromecreleasefrommitochondria
which in turn activates apoptosome formation and the effector
caspase-9. Here, we show using inhibitory RNA that BIM
knockdown in parent MCF7 cells phenocopies MCF-7TaxR,
implicating BIM as a key determinant of sensitivity to
paclitaxel. Consistent with the present results in MCF-7 cells,
knockdown of BIM reduced paclitaxel cytotoxicity in neuro-
blastoma cells but failed to protect against etoposide or
cisplatin-induceddeath.
12Inpartialagreementwiththis,inour
drug-resistant cell line MCF-7TaxR loss of BIM expression
was accompanied by a collateral increase in sensitivity to
cisplatin.Interestingly,weearliershowedthatthesensitivityof
P-glycoprotein-expressing MCF-7TaxR cells to etoposide was
unchanged compared with the parental cell line.
4 Previously,
upregulation of P-glycoprotein has been reported to result in
resistancetoetoposide.
13Assuch,ourdataobtainedforMCF-
7TaxR are somewhat unusual and imply that upregulation of
P-glycoprotein per se is insufﬁcient to mediate etoposide
resistance. It is also interesting to note that at the point
when resistance to paclitaxel became more marked in the
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Figure 6 (a) Reduction in cisplatin sensitivity of breast cancer cells following co-treatment with autophagy inhibitors. Data shown are IC50 values obtained using the MTT
assay and represent the means and S.D. for 43 repeat experiments. P-values were calculated using the paired Student’s t-test for IC50 cisplatin alone versus the IC50 for
combination of cisplatin with 3-methyladenine (3-MA) or LY294002. *Po0.05, **Po0.02. (b)I C 50 values obtained for MCF-7 cell lines treated with the mTOR inhibitor
rapamaycin. *Denotes a P-value of o0.02 (using a paired Student’s t-test). (c) Western immunoblotting of whole-cell lysate preparations of MCF-7 and paclitaxel-resistant
sublines treated with RAD001 (100nM) for 48h. Whole-cell lysates of control and drug-treated cultures were subjected to SDS-PAGE electrophoresis 10% Bis-Tris gels
(NOVEX), western transfer onto PVDF membranes and probing with primary antibodies to LC-3I/II (Cell Signaling Technology), survivin (Santa Cruz). Membranes were then
subjectedtoincubationwithasecondary-alkalinephosphatase-conjugatedantibodywithsubsequentchemiluminescentdetection.Allmembraneswerestrippedandreprobed
with an antibody to GAPDH (Sigma Aldrich), n¼3
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Cell Death and Diseasedeveloping MCF-7TaxR cells, this coincided with the dis-
appearance of BIM (passage #18).
Perhaps the most striking observation from our studies is
the switch from apoptosis to autophagy as the major
mechanism of cell death in MCF-7TaxR cells. A study which
looked at the autophagic response of ovarian cancer cells
treated with RAD001 reported that cisplatin-resistant cell lines
were signiﬁcantly more sensitive, supports our ﬁndings.
14
Cisplatin-sensitive MCF-7TaxR cells were markedly more
resistant to rapamycin, in line with a reciprocal relationship for
the sensitivity of cancer cells to these two agents. The
emergence of increasing sensitivity to platinum agents is of
particularinterestandisrelevanttothemanagementofbreast
andovariancancers.The datadescribing sensitivity ofMCF-7
cells to RAD001 are in close agreement with a report by Treck
etal.
15andotherdataweshowindicatesthatwhenautophagy
survival fails in the MCF-7TaxR line then death occurs
predominantly via autophagy. A study which looked at the
autophagic response of cisplatin- sensitive and -resistant
clear cell ovarian cancer cells when treated with RAD001 is in
some agreement with our current study (Mabuchi et al.
14),
which reported that cisplatin-resistant cell lines were shown to
be signiﬁcantly more sensitive to RAD001. In the current
study, cisplatin-sensitive MCF-7TaxR cells were shown to be
signiﬁcantly more resistant to rapamycin, suggesting a
reciprocal relationship for the sensitivity of cancer cells to
these two agents.
AKT has previously been described as an important
determinant of chemosensitivity for many kinds of cells.
14
Currently, we have shown that there was little evidence of
phospho-mTOR expression and no evidence for activation of
AKT when MCF-7TaxR cells were treated with staurosporine,
in line with an enhanced autophagic response, with modest
but nevertheless higher expression levels of these proteins
seen for parental MCF-7 cells. A report by Faried et al.
16
described signiﬁcant reductions in AKT induced following
paclitaxeltreatmentbutincreasesinphosphorylatedmTORin
cervical cancer cells. Further, the same report described a
lack of correlation between AKT levels and paclitaxel
sensitivity but a closer correlation was seen with mTOR
levels. RAD001 can effectively inhibit mTOR signalling and
this resulted in a marked reduction in phosphorylated p70S6K
with little effect on phospho-AKT expression in ovarian cancer
cells.
14 In agreement with this, we showed that staurosporine-
treated MCF-7TaxR cells markedly attenuated levels of the
mTOR substrate phospho-p70S6K. Conﬁrmation of the
marked autophagic response elicited in staurosporine-treated
MCF-7TaxR cells was seen in confocal images, where
marked LC3II formation was seen in MCF-7TaxR cells. In
contrast, rapamycin-resistant MCF-7TaxR variant cell lines
failed to undergo autophagic cell death following treatment
with RAD001. When the various paclitaxel-resistant sublines
of MCF-7 were subjected to treatment with RAD001, we saw
no evidence of formation of LC-3II, in line with the relative
resistance of these cells to the drug, compared with the
parental line. The disappearance of survivin in MCF-7-treated
cells is in some agreement with Kang et al.
17 who described a
cross talk between autophagy and apoptosis, wherein
degradationofsurvivinisseenviaabeclin-mediatedpathway.
AsbothpathwaysareoperativeforMCF-7cellsthiseffectwas
seen, but where there was an absence of functioning
apoptosis then survivin levels remained constant.
In order to explain the effects, we have seen in the
developing paclitaxel resistance of MCF-7 cells there are a
number of factors we can consider. A polyploidy state has
been described in resistance to paclitaxel
18 and indeed there
are many genes that are implicated in taxane resistance that
have roles in the maintenance of chromosomal stability.
19,20
Thus, paclitaxel is deemed to be more effective in cell
populations that are chromosomally stable, whereas thera-
pies such as trastuzumab have activity in more unstable cell
populations.
21 An aneuploid state with a high number of DNA
breakpoints has been associated with preferential sensitivity
to platinum agents in breast, ovarian and gastric cancers.
21
Finally, our data highlight the very important observation
that the absence of an apoptotic response results in abolition
of an MDR phenotype in the presence of P-glycoprotein
upregulation. A report by Johnstone et al.
22 described the
protection of leukaemic cells by the presence of upregulated
P-glycoprotein against caspase-dependent but not caspase-
independent cell death. This report corroborates our ﬁnding
that caspase-deﬁcient or caspase-inactivated, P-glycoprotein
expressing paclitaxel-resistant breast cancer cells do not
show cross-resistance with doxorubicin, colchicine or etopo-
side,asshownbythe presentstudy andpreviousworkbyus.
4
We did see, however, that the MDR-reversing agent
Tariquidar (XR9576) was able to reverse paclitaxel resistance
in the MCF-7TaxR line, whereas the sensitivity to the other
MDR-associated agents was unchanged. The basis for this
agent-speciﬁc effect is currently unclear and highlights the
complexity of the MDR phenotype.
In conclusion, we have shown that development of
resistance to the commonly used chemotherapeutic agent
paclitaxel gives rise to signiﬁcant molecular changes that
culiminate in a caspase-deﬁcient genotype dictating a
predominantly autophagic response to chemotherapeutic
agents. Our data also suggest that in the absence of multiple
caspases and also of several BCL2 family members marked
attenuation of MDR takes place. These ﬁndings have
implicationsforbreastcancertreatmentwherelowexpression
levels of caspases may be prevalent.
Materials and Methods
Chemicals and reagents. Reagents were obtained from Sigma Aldrich
(Poole, UK) unless stated otherwise. Staurosporine (Alexis Biochemicals,
Nottingham, UK), RAD001 (Selleck Chemicals, Houston, TX, USA), Z-VAD
(Bachem, Bubendorf, Switzerland), 3-methyl-adenine, LY294002, baﬁlomycin and
rapamycin were dissolved in dimethyl sulphoxide and stored as stock solutions;
doxorubicin was made up in sterile distilled water. Paclitaxel (Taxol; obtained from
Bristol Myers Squibb, Uxbridge, UK, as a pharmacy preparation) and cisplatin were
diluted in sterile 0.9% saline as stock solutions stored at  201C until use.
Cell culture. The human breast cancer cell line MDA-MB-231 (ATCC from LGC
Promochem, Teddington, UK) was cultured in L15-Leibovitz medium (Sigma
Aldrich). The human breast carcinoma MCF-7 cell line was obtained from the
European Collection of Cell Cultures (ECACC; Porton Down, Salisbury, UK) and
maintained at a low passage number throughout the study. Cell lines were
authenticated at source by STR proﬁling, morphology (ATCC) and DNA proﬁling
(ECACC). MCF-7 sublines were cultured in Dulbecco’s modiﬁed Eagle’s (Sigma
Aldrich)mediawith2mMofGlutamaxandsupplementedwith 10%heat-inactivated
foetal bovine serum (Invitrogen, Paisley, UK) at 5% CO2/371C. Cell lines with
acquired resistance to paclitaxel were generated by growth in incrementally
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MCF-7cellline withpaclitaxelresistance,designated MCF-7TaxR,wasmaintainedat
6nMpaclitaxelwithtreatmentatalternatepassages.TheestablishedMCF-7TaxRcell
linewasdesignatedasthosecultureswithpassagenumberexceeding23.Withdrawal
of paclitaxel from the culture medium in MCF-7TaxR cells at passage 40 with
subsequent culture as for parental cells over several weeks (49 months) resulted in
thecellvariantMCF-7TaxR( ).Thissublinewasdevelopedtoexaminethestabilityof
the drug-resistant phenotype. All cell lines were grown in drug-free media for at least
one passage before experimental use. Mycoplasma testing was carried out regularly
using a polymerase chain reaction (PCR) -based methodology.
Cytotoxicity testing. Human breast cancer cells MCF-7, MCF-7TaxR
passage 8, MCF-7TaxR passage 18 and MCF-7TaxR passage 23 were grown in
96-well plates at a density of 3 10
4/ml for 24h. Drugs were diluted in
supplemented tissue culture medium and added in increasing concentration, with
untreated wells as controls. Cells were then incubated for a period of 96h and
subjected to the 3-(4,5-dimethylthylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. This incubation period accounted for the doubling times of the cell
lines (which did not vary signiﬁcantly between parental and resistant variants) and
allowedforanapproximate10–20-foldincreaseincellnumberofcontrolcellsduring
this time period. For treatment with rapamycin and RAD001 cells were subjected to
staining with trypan blue and cell counting used as a measure of cell viability. This
method was also used to conﬁrm the MTT data previously obtained that indicated
paclitaxelresistanceforMCF-7TaxRcells,setupalongsideparentalMCF-7cellsfor
comparison. IC50 values (calculated as the dose necessary to cause a 50%
reduction in cell viability relative to untreated control cells) were calculated from
dose response curves using PRISM software.
AnnexinV withpropidiumiodide (PI)methodologyforapoptosis
with ﬂow cytometry. Cells were seeded into tissue culture ﬂasks to give
approximately 50% conﬂuence, allowed to attach for 2–3h and then treated for a
period of 24–48h with the appropriate compound at various concentrations (see
ﬁgure legends). Cells for treatment with the pan-caspase inhibitor Z-VAD (100mM)
were allowed to settle and then treated for 1h before treatment with staurosporine
(1mM) for 24h or with paclitaxel (20nM)or cisplatin(20mM) for a period of 48h. An
Annexin V–ﬂuoroscein-isothiocyanate (FITC)-conjugated apoptosis detection kit
incorporating PI was used as described by the manufacturer’s protocol (Oncogene;
suppliedbyCNBiosciences,Beeston,UK).Harvestingofcellsincludedcollectionof
attachedcellsfollowing trypsinisationandﬂoating cells,whichwere combinedin the
sampleforprocessing.AnalysisbyﬂowcytometryusedtheFL1(FITC)andFL3(PI)
laser lines and each sample was assessed using a collection of 10000 events.
Western blotting analysis. Whole-cell lysates were made from monolayers
of cultured cell in the exponential phase of growth. Cells were subjected to various
treatment protocols (as indicated in the ﬁgure legends) after seeding into tissue
culture ﬂasks at 30–40% conﬂuence and left to equilibrate for 24h. Cells were
harvested by scraping or by the use of a non-enzymatic cell dissociation ﬂuid,
washed twice in PBS and then resuspended in hypotonic lysis buffer containing
detergent and protease inhibitors. A 50-mg of membrane protein was loaded onto
SDS-PAGE gels and electrophoresed (Novex system, Invitrogen), and western
transferred to a polyvinylidene diﬂuoride membrane. Probing of the membranes for
b-actin or glyceraldehyde phosphate dehydrogenase (GAPDH) levels to act as
loading controls was carried out by membrane stripping with 1mM of sodium azide
in PBS for 1h followed by incubation using murine antibody to actin or GAPDH
(Sigma Aldrich). Visualisation was carried out using anti-rabbit or anti-mouse
alkaline phosphatase-conjugated secondary antibody (WesternBreeze) with
chemiluminescent substrate (CDP Star) both obtained from Invitrogen.
Qualitative PCR analysis. RNA was extracted from monolayers of human
breast cancer cell lines using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. Quantitiave PCR analysis was carried out using
SYBRgreen reagent (One-step QuantiTect Qiagen, Crawley, UK). Primers for
caspases-7 and -9 were from SuperArray (obtained from Tebu-Bio, Leicester, UK).
ThePCR reactions were carriedout usingthe TaqMan 700ABI Prism with software
from Applied Biosystems (Life Technologies, Paisley, UK), setting the cycles as
follows: 30min/501C for reverse transcription; 15min/951C PCR initial activation
step; 40 cycles of denaturation for 20s/951C and annealing step for 60s/601C.
Fold changes were calculated using the formula 2ð DDCtÞ, where DDCt is the
DCt(gene of interest) DCt(GAPDH) and Ct is the cycle at which the threshold is crossed.
Transfection with BCl2-interacting mediator of cell death (BIM)
small interfering RNA (SiRNA). MCF-7 cells were subjected to transfection
withSiRNA toBIM(Dharmacon;distributed byThermoScientiﬁc/AbGeneLtd,Epsom,
UK) reagent SiGENOME (product code D-004383-20), target sequence:
50-GUUCUGAGUGUGACCGAGA-30, using transfection reagent DharmaFECT1
(product code T-2001-02) according to manufacturer’s instructions with OPTIMEM
medium (Invitrogen). The appropriate negative controls were used according to the
manufacturer’s protocols.
Acridineorangestainingfordetectionofacidicvesicles. Inorderto
detect and quantify the acidic vesicle formation during the process of autophagy,
MCF-7 cell lines were exposed to 1mM staurosporine treatment for 24h. Cells were
thenharvestedbytrypsinisation.CellswerewashedtwicewithPBSandthenstained
with acridine orange solution (Sigma Aldrich) at a ﬁnal concentration of 2ng/ml for
30min in the dark. Acridine orange is a weak base that can accumulate in acidic
spacesandemitsbrightredﬂuorescence (measuredatFL4).Theintensityofthered
ﬂuorescence is proportional to the degree of acidity and/or volume of the cellular
acidic compartments. Baﬁlomycin treatment is used to inhibit the autophagosome
formation.Theextentofautophagy(asa%ontheFL4scale)isthusassessedasthe
extent of red ﬂuorescence minus that seen in the presence of baﬁlomycin.
Fluorescence confocal microscopy for detection of LC3. Cells were
seeded into T25cm
2 tissue culture ﬂasks at densities of 2 10
5 (MDA-MB-231) or
3 10
5(MCF-7,MCF-7TaxR)andleftfor24hunderstandardcultureconditions.Cells
were then treated with a sub-cytotoxic dose of staurosporine at a dose of 0.25 or
0.5mM for a further 24h. Cells were harvested using standard trypsinisation with
collectionoftheﬂoatingcellpopulationandprocessedusingtheCytospin4cytological
centrifuge (ThermoElectron Corporation, Basingstoke, UK). The cytospin slides were
then ﬁxed in 2–4% paraformaldehyde/PBS for 15min and rinsed in PBS. Slides were
then covered in ice-cold methanol and kept at  201C for 10min (permeabilisation
stage). Following PBS rinsing slides were blocked with 5% goatserumfornon-speciﬁc
binding for 1h. This was then followed by overnight incubation with primary antibody
(LC-3B; Cell Signaling Technology) at a dilution of 1:200 in PBS-Triton, in a
humidifying chamber at 41C. Slides were then washed with PBS and incubated
with the secondary antibody conjugated to Alexa-Fluor488 anti-rabbit secondary
antibody (MolecularProbes, Invitrogen)for 2h. After rinsing with PBSthen the nuclear
dye TOPRO3 (Nuclear Probes, Invitrogen) was applied for 10min with a ﬁnal washing
usinghigh-saltPBS.Slideswerelefttoair-dryandthenAnti-Fadereagentformounting
was used on a coverslip. The edges of the slides were then sealed with standard
commercially available nail lacquer. Images were produced by confocal microscopy
using a Carl Zeiss Laser Scanning System, LSM510 at  40 magniﬁcation.
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